Genmab Commences Binding Arbitration of Two Matters Under License Agreement with Janssen

Copenhagen, Denmark; September 22, 2020 Genmab A/S (Nasdaq: GMAB) announced today that it has commenced binding arbitration of two matters arising under its license agreement with Janssen Biotech, Inc. (Janssen) relating to daratumumab.